Clearline Capital’s iTeos Therapeutics ITOS Stock Holding History

Clearline Capital’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-55,013	Closed	-$548K	–	122
2025 Q2	$548K	Buy	+55,013	New	+$443K	0.02%	101
2024 Q4	–	Sell	-167,417	Closed	-$1.71M	–	127
2024 Q3	$1.71M	Buy	167,417 +10,523	+7%	+$161K	0.07%	105
2024 Q2	$2.33M	Buy	+156,894	New	+$2.25M	0.06%	87

Other funds holding ITOS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Clearline Capital's ITOS Position: Q3 2025 in Review

Clearline Capital sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 55,013 shares — an estimated $548K sold.

Clearline Capital first reported a position in ITOS in Q2 2024 and held it in 3 quarters. The position peaked at $2.33M in Q2 2024. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.

Clearline Capital reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
Clearline Capital sold 55,013 iTeos Therapeutics shares in Q3 2025, an estimated $548K.
Clearline Capital first reported a position in iTeos Therapeutics in Q2 2024 and held it in 3 quarters.
Clearline Capital's iTeos Therapeutics position peaked at $2.33M in Q2 2024.
1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.

Based on Clearline Capital's 13F filing for Q3 2025, filed 14 Nov 2025.